HomeAI · summaries
Storia in 4 fonti
Agios Reports Neutral Sickle Cell Data, Decides To Stop Development - Agios Pharmaceuticals (NASDAQ:AGIO)
Agios Pharmaceuticals stops tebapivat development in sickle cell disease after Phase 2 study fails to prove meaningful differentiation.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Agios scraps sickle cell drug
The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.
- ·
investors.com
Why This Novo Rival Just Pulled A Bearish Move
Agios Pharmaceuticals dropped its next-generation sickle cell drug Tuesday after a failed Phase 2 study. Agios stock tumbled.
